Eli Lilly Reports Positive Phase 3 Results for Obesity Treatment Retatrutide Showcasing Significant Weight Reduction Federal Judge Accused of Sexual Misconduct in Chambers With Police Officer Disciplinary Panel Reveals Tulsi Gabbard Resigns as US Intelligence Chief Amid Iran Strike Considerations IBM Gains 27 Billion in Market Cap After Trumps 2 Billion Quantum Computing Push International Aid Sector Faces Breaking Point as Legacy Models Struggle Under Funding Pressures Subramanian Swamy Calls for Ban on Cement Imports From Pakistan Over Security Concerns MPT Q1 2026 Earnings EPS Surges Past Estimates With 65 Beat Stock Slides Slightly SPNT Q1 2026 Earnings Earnings Surpass Estimates by 178 Despite Slight Stock Decline Novagold Resources Inc NG Q1 2026 Earnings EPS Exceeds Estimates as Company Maintains Focus on Donlin Gold Project PONY Q1 2026 Earnings Narrower Loss Per ADS Drives Positive Investor Sentiment BrightView Holdings BV Q1 2026 Earnings EPS Misses Estimates Amid Strategic Execution MKTW Q1 2026 Earnings Deep EPS Miss Overshadowed by Modest Stock Recovery Strive Inc ASST Edges Lower Amid Cautious Trading Key Support Levels in Focus Everbright Digital Holding EDHL Surges 1012 to 283 Testing Key Resistance at 297 Brunswick Corporation BC Edges Higher as Marine Recreation Demand Stabilizes Oklo Inc OKLO Surges 338 as Stock Approaches Key Resistance Level Allied Gaming Entertainment AGAE Slips 37 Testing Key Support at 056 Conduent CNDT Q1 2026 Earnings Earnings Surprise Lifts Shares Amid Turnaround Efforts BSRR Q1 2026 Earnings Earnings Surpass Estimates on Improved Operating Performance BAM Q1 2026 Earnings Narrow EPS Miss Amid Steady Asset Management Operations CACC Q1 2026 Earnings A Narrow Miss in a Challenging Auto Lending Environment SYRE Q1 2026 Earnings WiderthanExpected Loss Highlights Development Stage Challenges XFOR Q1 2026 Earnings NarrowerThanExpected Loss Despite Flat Revenue ATT CEO Highlights BlueCollar Worker Demand as AI Reshapes US Labor Market RYZ Q1 2026 Earnings EPS Misses Estimates Amid Challenging Conditions Stock Gains 487 Kymera Therapeutics KYMR Shows Modest Upside as Biotech Sector Stabilizes